Lyell Immunopharma (LYEL) Non-Current Deffered Revenue (2020 - 2022)

Lyell Immunopharma's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $37.2 million for Q3 2022.

• In Q3 2022, Non-Current Deffered Revenue fell 54.61% year-over-year to $37.2 million; the TTM figure through Sep 2022 stood at $37.2 million (down 54.61% YoY), while the FY2021 annual figure was $79.7 million, down 10.56% from the prior year.
• Non-Current Deffered Revenue came in at $37.2 million for Q3 2022 at Lyell Immunopharma, up from $32.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $89.1 million in Q4 2020 to a low of $32.9 million in Q2 2022.
• A 3-year average of $68.6 million and a median of $79.7 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue declined 10.56% in 2021 and plunged 59.79% in 2022, its largest moves.
• Lyell Immunopharma's Non-Current Deffered Revenue stood at $89.1 million in 2020, then dropped by 10.56% to $79.7 million in 2021, then tumbled by 53.35% to $37.2 million in 2022.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $37.2 million, $32.9 million, and $77.9 million for Q3 2022, Q2 2022, and Q1 2022 respectively.

Peer Comparison